Sponsors

Aiforia to provide AI solutions for cancer diagnostics for Fimlab Laboratories

Fimlab Laboratories has selected Aiforia Technologies as the provider for breast and prostate cancer diagnostics solutions. Fimlab is Finland’s largest healthcare laboratory company, owned by the wellbeing services counties of Pirkanmaa, Central Finland, Kanta-Häme, Ostrobothnia, and Päijät-Häme.

Earlier this year, Aiforia announced a framework agreement in which it was selected as one of the suppliers of AI solutions for Fimlab to support pathology diagnostics. Three best suppliers were chosen for AI models for nine applications and a development platform for AI models. Aiforia was qualified as one of the suppliers for eight applications and the development platform.

The AI solutions for breast and prostate cancer, representing three applications, are the first order for Aiforia within the multi-year framework agreement. The value of this first order for Aiforia is approximately €300,000 for the first year.

“We are extremely excited to officially kickstart this cooperation. Fimlab is a true pioneer in Finland in adopting AI solutions to support diagnostics in pathology. It is an honour to be part of this progressive step in our home country,” says Jukka Tapaninen, CEO of Aiforia.

 

Latest Issues

DIA-MHRA Global Summit

Senate House, Malet Street, London, WC1E 7HU
16-17 November, 2026

UK NEQAS for Microbiology & Parasitology Annual Scientific Meeting 2026

The Royal National Hotel, 38 – 51 Bedford Way, London, WC1H 0DG
27 November, 2026

UK NEQAS webinar: Epigenetics

Online
1 December, 2026

Weqas Annual POCT Conference 2026

London, Venue - TBC
8-9 December, 2026

UK NEQAS webinar: Fresh Muscle Biopsies

Online
8 December, 2026